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COMPLEMENT activation has a critical role in the 
rejection of vascularized organs transplanted be-
tween related and widely separated species. I .2 In June 
1992 and in January 1993 we undertook two baboon-to-
human liver xenotransplantations. The serum levels ofC3. 
C4, total hemolytic complement activity (CH 11Xl)' and 
circulating immune complexes (IC) were monitored. The 
objective was to see if there was an association of antibody 
and complement activation with the rejection of these liver 
xenografts. 
MATERIALS AND METHODS 
Two patients. aged 35 and 62 years respectively, both suffered 
from end-stage liver disease secondary to hepatitis B virus (HBV) 
infection. Detailed descriptions of the donor and recipient opera-
tions and immunosuppression drug doses and their blood levels 
have been reported elsewhere. 3 
C3 and C4 Levels 
C3 and C4 levels were measured by rate nephelometry (Beckman 
Array, Beckman Instrument Co, Brea, Calif). 
Total Hemolytic Complement Activity (CH1co) 
The test is based on the ability of complement to lyse red blood 
cells. The serum to be tested diffused radially from wells in 
agarose gel, which contained standardized sheep erythrocytes 
sensitized with hemolysin. An estimate of CH]{)o was made by 
comparison of the extent of lysis caused by the test serum sample 
with that caused by reference sera, run simultaneously. The 
results were reported in units/mL (normal value> 60 U1mL). 
Detection of Circulating Immune Complexes 
These complexes were qualitatively detected using zone electro-
phoresis on agarose gels. 4 In essence, an antibody-antigen im-
mune complex has a net surface charge different from the isolated 
constituents. This property, together with the clonal restriction of 
the antibody response, gives rise to distinctive patterns that are 
apparent in stained agarose gels after routine zone electrophore-
sis. 
~ \RESULTS 
Table 1 shows the results obtained from both patients. 
CHICO activity before xenotransplantation was below the 
limit of detection «21 U/mL) in both patients, along with 
abnormally low C3 and C4levels, which is characteristic of 
end-stage liver disease. IC were detected before transplan-
tation only in patient 1. 
After xenotransplantation, IC were detected from days 1 
to 9 in patient 1, and were not detected at any time in 
patient 2. CHICO activity was below the limit of detection 
Table 1. Circulating Immune Complexes, Total Hemolytic 
Complement Activity, and C3 and C4 Levels After 
Baboon-ta-Human Liver Xenotransplantatlon 
CH,oo C3 C4 
Day IC (U/ml) (mgldl) (mg/dl) 
Patient 1 Pre-Tx + <21 35 7 
1 + <21 33 3 
3 + <21 27 3 
5 + <21 27 5 
7 + <21 33 6 
9 <21 40 8 
11 21 29 6 
17 55 64 17 
Patient 2 Pre-Tx <21 43 7 
1 <21 30 6 
3 36 7 2 
5 40 35 6 
7 32 34 5 
9 S3 40 6 
11 38 7 
17 59 71 8 
IC: immune complexes; CH,oo: Tolal hemolytic complement activity (NV > 60 
U/ml); C3: NV 83-177 mgldl: C4: NV 15-45 mgldl. 
during days I to 11 in patient 1. and during days I and 2 in 
patient 2. CHICO activity in both patients was associated 
with a reduction in C3 and C4 serum levels. At this time, 
liver biopsies showed an increase ofIgG, IgM antibodies, 
and complement deposition in hepatic sinusoids in liver 
biopsy specimens. 
DISCUSSION 
The liver is the main site of complement synthesis. 5 .6 The 
significant reduction of C3 and C4, along with CH 100 below 
the limit of detection before transplantation, is known to 
be secondary to the end-stage liver disease and a reduction 
in complement synthesis. This could Contribute to avoid-
ance of hyperacute rejection in these two baboon-to-
human liver xenotransplantations. 
Patient 1 had circulating IC before transplantation, 
which persisted during the first 9 days after transplanta-
tion. In contrast, IC were not detected before nor after 
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transplantation in patient 2. The correlation between dis-
appearance of circulating IC with detection of CH lOo 
activity in patient I suggested that the complement pro-
duced by the new liver was primarily used to remove 
circulating I C. 7 Reductions of C3 and C4 at the time of 
CH 100 activity have been associated with activation of the 
classic antibody-dependent complement pathway in exper-
imental models of xenotransplantation between closely 
related species. 2 One interpretation of our results could be 
that when complement levels reached a functional level, a 
humoral reaction occurred in the liver xenograft. reflected 
by an impainnent of the liver function tests and extensive 
deposits of immunoglobulins (IgG and IgM) and comple-
ment (C3 and C4) in the liver biopsy specimens. These 
deposits largely disappeared 12 days later. s 
In summary, the complement activation in our baboon-
to-human liver xenotransplantations did not result in hy-
peracute rejection, but we believe that the xenograft was 
damaged by a mechanism similar to the Schwartzman or 
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local Arthus reactions. New approaches to control com-
plement activation should be included among the thera-
peutic strategies in baboon-to-human xenotransplantation. 
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